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Composite outcomes comprising more than one clini-
cally relevant end point are used in clinical trials where
there is no single important outcome or the outcome is
very rare. Pre-eclampsia is associated with significant
maternal and neonatal complications and delivery is
often expedited to minimise complications. There is a
need for a randomised trial to evaluate the timing of
delivery in women with mild to moderate pre-eclampsia
at late preterm gestation. No single outcome has been
identified to be the most clinically important, reflecting
the multisystemic nature of pre-eclampsia. We developed
composite maternal and neonatal outcomes to be consid-
ered as the primary outcome measure for a clinical trial
in this area.
A two-generational Delphi method was used to identify
these clinically important maternal and neonatal out-
comes. Composite outcomes were developed based on
biological plausibility, independence from each other,
equal importance and frequency of occurrence. The final
maternal composite outcome included maternal death,
eclampsia, stroke or reversible ischaemic neurological defi-
cit, pulmonary oedema, major obstetric haemorrhage,
infusion of a third anti-hypertensive or need for positive
ionotropic support, HELLP (haemolysis, elevated liver
enzymes and low platelets) syndrome and placental abrup-
tion; and the neonatal composite outcome included neo-
natal death, respiratory distress syndrome needing
ventilator support and neurological outcomes as cystic
periventricular leukomalacia and grade III/IV intraventri-
cular haemorrhage.
The composite outcomes developed will enable clinical
trials on the timing of delivery in women with mild to
moderate pre-eclampsia to provide robust estimates for
the intervention to be implemented in clinical practice.
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